Death · patients with schizophrenia
Comparison 1: PERPHENAZINE showed no clear difference in death compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Response to treatment ‐ medium term · patients with schizophrenia
Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 1. General ‐ at least one adverse effect compared with low‐potency antipsychotic drugs (moderate certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 2.a. Specific ‐ movement disorders ‐ at least one… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Death · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
No response · people with psychosis
1 finding from 1 review
Symptomatic hyperprolactinaemia · people with psychosis
1 finding from 1 review
Use of antiparkinsonian medications · people with psychosis
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS… compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review